Who Paid My Doc
Sendhilnathan Ramalingam
Medical Oncology Durham, NC Medical Doctor
NPI 1164818126 CMS profile 9262994
2301 Erwin Rd, Ste 5000, Durham, NC 27705
General payments
$6,782
Research payments
$1,475
Ownership & investment interest
$0
Through program year 2025, Sendhilnathan Ramalingam of Durham, NC is reported in the CMS Open Payments database as having received $6,782 across 7 general payments and $1,475 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 59th percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $6,782 | 7 | |
| 2025 | Research | $1,475 | 13 |
Beside peers
- Sendhilnathan Ramalingam
- Medical Oncology median
- Middle half of Medical Oncology
- National median
In program year 2025, general payments to Sendhilnathan Ramalingam were reported at $6,782. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.
Show as a table
| Year | Sendhilnathan Ramalingam | Medical Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $968 | $140–$6,658 | $163 |
| 2020 | $0 | $747 | $102–$5,891 | $114 |
| 2021 | $0 | $430 | $50–$4,098 | $132 |
| 2022 | $0 | $812 | $127–$4,907 | $149 |
| 2023 | $0 | $957 | $144–$5,248 | $160 |
| 2024 | $0 | $1,042 | $149–$5,650 | $164 |
| 2025 | $6,782 | $1,128 | $147–$5,675 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 48 drugsPart D claims
2,528
Drug cost
$11,586,268
Branded share of claims
29.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Lenalidomide | Generic | 244 | $3,236,731 | |
| Revlimid Lenalidomide | Brand | 108 | $1,923,532 | |
| Empaveli Pegcetacoplan | Brand | 26 | $1,107,105 | |
| Imbruvica Ibrutinib | Brand | 52 | $870,034 | |
| Venclexta Venetoclax | Brand | 56 | $675,924 | |
| Pomalyst Pomalidomide | Brand | 31 | $650,478 | |
| Jaypirca Pirtobrutinib | Brand | 23 | $546,793 | |
| Calquence Acalabrutinib Maleate | Brand | 27 | $412,720 | |
| Xpovio Selinexor | Brand | 13 | $400,414 | |
| Ojjaara Momelotinib Dihydrochloride | Brand | 14 | $396,477 |
The 10 drugs with the highest cost, of 48 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 13 billing codesPaid by Medicare
$145,273
Medicare patients
376
Services billed
2,538
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 45% | |
| Chronic kidney disease | 37% | |
| Ischemic heart disease | 36% | |
| Diabetes | 30% | |
| Heart failure | 28% | |
| Atrial fibrillation | 27% | |
| Cancer | 26% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
20 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Medical Oncology in North Carolina
Related records
Medical Oncology in North Carolina
Practitioners in the same specialty and state, ranked by reported value.
All Medical Oncology
Everyone recorded under this specialty, nationwide.
Doctors in North Carolina
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.